Achieve Life Sciences outlines expedited FDA review for cytisinicline and targets Q3/Q4 2026 launch
Source: SeekingAlpha
2025-11-06 15:27:12 ET
More on Achieve Life Sciences
- Achieve Life Sciences, Inc. (ACHV) Q3 2025 Earnings Call Transcript
- Achieve: Expedited Review Of Cytisinicline Sets The Stage For Development Expansion
- Achieve Life Sciences: Promising Pipeline But High Risks Makes Me Hold For Now
- Achieve Life Sciences Q3 2025 Earnings Preview
- Achieve, Disc, Revolution among winners of initial FDA national priority vouchers
Read the full article on Seeking Alpha
For further details see:
Achieve Life Sciences outlines expedited FDA review for cytisinicline and targets Q3/Q4 2026 launch
Achieve Life Sciences Inc.
NASDAQ: ACHV
ACHV Trading
-4.23% G/L:
$4.26 Last:
190,740 Volume:
$4.36 Open:
ACHV Latest News
March 04, 2026 08:00:00 am
Achieve Life Sciences Presents Data at SRNT Demonstrating Successful Cessation in Smokers with Extensive Prior Treatment Exposure; and on Participant Experience in the ORCA-OL Study
January 12, 2026 08:47:00 am
Achieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical Officer
December 08, 2025 04:10:53 pm
Achieve Life Sciences Announced Granting of New Hire Inducement Awards
November 06, 2025 07:00:00 am
Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program
ACHV Stock Data
$234,761,887
51,636,968
N/A
28
N/A
Biotechnology & Life Sciences
Healthcare
CA
Bothell
